Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hoshi Iryo-Sanki Co., Ltd. (7634.T)
Tokyo, JP
Hoshi Iryo-Sanki Co., Ltd., a Japanese firm, specializes in the production and distribution of pharmaceutical-grade medical oxygen and nitrous oxide. Its business activities are structured across five distinct divisions: Medical Gas, Home Healthcare, Medical Gas Equipment Construction, Nursing Care, and Facilities Nursing. The Medical Gas division primarily handles the sale of various medical gases, including oxygen and anesthetic gases. Through its Home Healthcare division, the company offers rental services for essential medical devices, such as oxygen concentrators for home therapy, continuous positive airway pressure (CPAP) machines, and home ventilators. The Medical Gas Equipment Construction segment is responsible for the planning, installation, and subsequent maintenance and inspection of medical gas piping systems. The Nursing Care division provides a comprehensive suite of services, encompassing the rental and sale of care-related products, home modifications, and direct nursing assistance through home visits and in-home care coordination. Lastly, the Facilities Nursing division manages and operates fee-based residential nursing homes and day care centers, along with other related services. Established in 1960, the company's main offices are situated in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.72% | -4.11% | -8.07% | -3.92% | +2.94% | -4.11% | +9.74% | +22.50% | +26.94% | +51.47% | +104.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Equipment & Services: +14.1%+2.8% Q1'26: +1.6% (vs Q1'25)
-
EPS growth Medical - Equipment & Services: +15.4%-6.3% Q1'26: -15.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Equipment & Services: -3.5%+13.1% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Equipment & Services: +1.1%+12.4% ★ Q1'26: +14.8% (vs Q1'25)
-
ROIC Medical - Equipment & Services: +2.4%+12.8% ★ Q1'26: +17.1% (vs Q1'25)
-
Share dilution Medical - Equipment & Services: -2.1%+0.1% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Equipment & Services: 0.31×0.45× ★ Q1'26: 0.36× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2020 actual |
|---|---|
| Revenue |
10.88B
est: 11.10B (-2.0%)
|
| EBITDA |
1.72B
est: 2.17B (-20.6%)
|
| EBIT |
1.04B
est: 1.46B (-28.9%)
|
| Net Income |
734.86M
|
| SGA |
4.33B
est: 2.45B (+76.8%)
|
| EPS |
224.88
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Masanari Hoshi | Executive Chairman of the Board of Directors | 117M | male |
| Kazuhiro Hayamizu | Manager of Medical Facility Business Department, Executive Officer & Director | — | male |
| Keiichiro Aoki | Full-Time Audit & Supervisory Board Member | — | male |
| Masahiro Hoshi | Chief of President's Office, Senior MD & Director | — | male |
| Mitsuo Nukagari | MD, GM of Sales, Head of Iwate, Tohoku, Koriyama, Tochigi, Ibaraki, Chiba, Hokk, Kyushu and Director | — | male |
| Yasuyuki Suzuki | Manager of Tokai Region & Director | — | male |
| Yoshimi Takahashi | Accounting Manager | — | female |
| Yukio Hoshi | President, Chief Executive Officer & Representative Director | — | male |
| Daisuke Tokunaga | Director and In Charge of Kansai & Chugoku-Shikoku Region | — | male |
| Yukio Mogaki | SMD, Head Chiba, Mat, N. Kan, S. Tok, Kei, Yo., Kan., Sei, Kyo, Kof Reg., GM of Pur. and Adm & Dir | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7634.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
